NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Amphastar Pharmaceuticals, Inc. AMPH
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$719.9M
▼ 1.7% vs FY2024
EPS · FY25
$2.03
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
13.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 719.9M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
14 cents of every revenue dollar became profit this year.
Per share
USD 2.03
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin19.5%
Net margin13.6%
Return on assets6.1%
Returned to shareholders
USD 69.2M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 69.2M
Share of profit70.5%
Consecutive raises—
USD 69.2M in buybacks — 71% of the year's profit went back to shareholders.
Growth
+15.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.0%
+15.5%
+11.1%
Net income
+2.4%
+133.8%
EPS, diluted
+5.3%
+132.3%
Returned to shareholders
+49.5%
+299.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years−3.9%
Change, 10 years+1.0%
The share count shrank 4% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.6B
total assets, end of FY2025
Total assetsUSD 1.6B
CashUSD 170.2M
Gross debtUSD 619.7M
Net debtUSD 449.5M
Current ratio4.02×
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.7
0.7
0.6
0.5
0.4
0.3
0.3
0.3
0.2
0.3
0.3
0.2
0.2
0.2
Operating income $B
0.1
0.2
0.2
0.1
0.1
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
EBITDA $B
0.2
0.2
0.2
0.1
0.1
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
Net income $B
0.1
0.2
0.1
0.1
0.1
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
EPS, diluted $
2.03
3.06
2.60
1.74
1.25
0.03
0.98
−0.12
0.08
0.21
−0.06
−0.25
0.31
0.46
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
20.5
14.7
0.4
13.7
−1.7
1.1
3.1
−1.0
−4.0
4.9
7.8
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed